Challenges, Limitations, and Future Perspectives

While the evolving understanding of PAMP and DAMP biology has provided profound insights into both immune regulation and the modulation of nonimmune cellular dynamics, several critical challenges and limitations remain unresolved.

First, conventional models often oversimplify the spatiotemporal complexity of danger signaling in vivo. A central theme of this review is the contextual duality of danger signals: although PAMPs and DAMPs evolved to protect the host by driving pathogen clearance and tissue repair, their dysregulation can fuel chronic inflammation and tissue damage. This duality is especially evident during severe infections, where the very immune responses necessary for pathogen elimination can culminate in systemic immunopathology and organ dysfunction. Similarly, in the tumor microenvironment, these signals act as a double‐edged sword. They can either prime robust antitumor immunity or foster an inflammatory niche that promotes tumor progression and immune evasion. While recent studies indicate that this context‐dependency is governed by molecular properties (such as redox states and other posttranslational modifications), signal concentration, exposure duration, and the local tissue microenvironment, a comprehensive understanding of this duality remains elusive. Furthermore, although the synergistic and antagonistic interactions between PAMPs and DAMPs have been outlined here, the precise molecular mechanisms underpinning their crosstalk require deeper investigation. It remains largely unclear how these signals integrate to cooperate or compete within distinct cellular landscapes.

Second, from a diagnostic perspective, the clinical utility of these danger signals is constrained by substantial methodological limitations. Standard detection platforms primarily quantify total protein pools and remain largely blind to the functionally distinct isoforms that govern specific biological activities. Furthermore, the rapid extracellular degradation of these molecules and their subsequent dilution in the peripheral circulation significantly diminish their accuracy and reliability as real‐time proxies for localized tissue damage.

Third, therapeutic targeting of the PAMP/DAMP axis necessitates a delicate clinical balance. In hyperinflammatory states, such as sepsis or acute autoimmune disorders, the broad‐spectrum neutralization or aggressive clearance of danger signals may inadvertently compromise the host's fundamental ability to combat primary or secondary infections. Conversely, in the context of cancer immunotherapy, the deliberate induction of immunogenic cell death or trained immunity must be carefully titrated to prevent excessive systemic inflammation or drug‐induced autoimmunity. Consequently, the extent of signal clearance, the precise therapeutic window, and the underlying disease context are critical variables that must be rigorously addressed during drug development. Future therapeutic strategies must evolve from broad inhibition toward precise, time‐sensitive modulation of these pathways.

Moving forward, overcoming these translational barriers requires a fundamental shift toward high‐resolution, multidimensional methodologies. First, the integration of single‐cell multi‐omics (encompassing transcriptomics, epigenomics, and metabolomics) will enable the identification of rare sentinel cell subpopulations that orchestrate PAMP/DAMP responses, potentially uncovering novel therapeutic checkpoints. Second, spatial transcriptomics and multiplexed imaging can map the in situ distribution of danger signals and their cognate receptor activation within tissues, providing a detailed view of regional heterogeneity that remains fundamentally unattainable through conventional bulk tissue analysis. On the therapeutic front, advancing precision nanomedicine and targeted delivery systems will facilitate the spatiotemporally controlled release or sequestration of these molecules. Such innovations will ultimately maximize therapeutic efficacy while safeguarding systemic immunological homeostasis.